<DOC>
	<DOCNO>NCT00702338</DOCNO>
	<brief_summary>The objective follow-up study P05713 evaluate whether corifollitropin alfa ( Org 36286 ) treatment induction monofollicular growth woman underwent ovulation induction ( OI ) base study P05693 ( NCT00697255 ) safe pregnant participant offspring .</brief_summary>
	<brief_title>Pregnancy Neonatal Follow-up Ongoing Pregnancies Established Clinical Trial P05693 ( P05713 )</brief_title>
	<detailed_description>Base study P05693 ( NCT00697255 ) plan include two separate stage ( Ia+Ib II ) . Stage Ia open-label uncontrolled small cohort woman ( n=5 ) explore whether intended dose regimen corifollitropin alfa follow daily low dose recombinant Follicle Stimulating Hormone ( recFSH ) would provide appropriate response eligible participant meet inclusion none exclusion criterion . Stage Ib open-label uncontrolled small cohort woman ( n=3 ) explore whether intended dose regimen corifollitropin alfa follow daily low dose Human Chorion Gonadotropin ( hCG ) would provide appropriate response eligible participant meet inclusion none exclusion criterion . Stage II plan open-label randomized ( n=40 ) evaluate whether intend dose regimen corifollitropin alfa follow low dose recFSH ( n=20 ) hCG ( n=20 ) would provide appropriate response eligible participant meet inclusion none exclusion criterion . P05713 follow-up ( FU ) study prospectively monitor pregnancy , delivery , neonatal outcome woman become ongoing pregnant base study P05693 ( NCT00697255 ) . For trial , study specific assessment require treatment administer , information obtain standard practice use . Enrollment begin first ongoing pregnancy result base study establish ( ultrasound â‰¥ 10 week bolus injection hCG ) .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Participants participate base study P05693 ( NCT00697255 ) receive least one dose corifollitropin alfa Ongoing pregnancy confirm ultrasound least 10 week bolus injection hCG base study P05693 Able willing give write informed consent ( informed consent incorporate informed consent form protocol P05693 )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Neonatal outcome</keyword>
	<keyword>Congenital malformation</keyword>
	<keyword>Ovulation Induction</keyword>
	<keyword>Follow-up</keyword>
</DOC>